Pfizer (PFE) recently announced positive topline results from the Phase 3 EV-303 clinical trial, showcasing promising outcomes for PADCEV in treating muscle-invasive bladder cancer. Over the last ...

Pfizer (PFE) recently announced positive results from its Phase 3 EV-303 clinical trial in collaboration with Astellas Pharma ...

The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a clinical study titled ‘A Phase 1/2A Dose ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The recent portfolio rebalance increased FDL's risk and volatility, with 55% concentration in its top 10 holdings. Read why I ...

Summit Therapeutics, which has consistently been communicating quarterly results through investor calls in the past few years ...

Pfizer Inc. has just upgraded its 2025 earnings forecast, fueling a bullish sentiment among analysts. After its Q2 earnings ...

These five large-cap value dividend stocks look poised to provide some second-half gains with steady ultra-high-yield ...

Chasing a 100 times return might not be a great idea. But there are lessons to be taken from past winners of this magnitude.